ArticleIn vivo (Athens, Greece)
Nattokinase Attenuates Acute Cerebral Infarction in a Rat Model of Middle Cerebral Artery Occlusion.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimNattokinase (NK) is a potent serine protease with various pharmacological properties that include thrombolytic, anti-inflammatory, and antioxidant activities. The aim of this study was to investigate the neuroprotective effects of NK in transient middle cerebral artery occlusion (MCAO)-induced cerebral ischemia-reperfusion injury and determine the mechanisms underlying the effects of NK. MATERIALS AND
methodsRats were administered NK (65 and 130 mg/kg body weight, p.o.) daily for seven days prior to MCAO surgery. The infarct volume, behavioral tests, clotting time, and antioxidant markers in the MCAO model rats were assessed. The involvement of various cellular pathways in the effects of NK was examined.
resultsNK treatment dose-dependently reduced infarct volume and prolonged clotting time in MCAO model rats. Transcription factor activity analysis revealed the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2) activity and enhanced antioxidant enzyme expression following MCAO.
conclusionOral nattokinase confers early neuroprotection after experimental cerebral ischemia through Nrf2-associated antioxidative modulation and a mild, transient anticoagulant effect, supporting its potential as an orally available adjunct in ischemic stroke management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.